Author Topic: Bronchitis Cough  (Read 165 times)

glennaguilar

  • Administrator
  • Hero Member
  • *****
  • Posts: 3346
    • View Profile
Bronchitis Cough
« on: September 30, 2016, 11:52:17 am »
Bronchitis Cough - Tracheal Bronchitis  - What Medical Science Has Newly Revealed
When medical professionals enter their career, they have to be careful when diagnosing a patient. Often times, symptoms of one illness can be having symptoms to another illness. It's because of this that doctors have to be very careful and provide an accurate diagnosis, combine that with the right type of treatment of medicine.

Bronchitis remains a large threat to public health, ranking fourth among causes of death. A new strain recently revealed is making treating this disease even harder because of its nature. The newly discovered strain is even nastier in that it can resist conventional medicines. It's forcing doctors to revise their techniques pertaining to both illness of pneumonia and bronchitis. We have not included any imaginary or false information on Medicine Bronchitis here. Everything here is true and up to the mark!

Nowadays, There is Some Controversy With How to Treat the Disease
Some doctors feel it is in the best interest of the patient to use no medicine treatment therapy especially when a cough does not last for more than five days.  Others feel medicinal therapy is the way to go. Patients are typically treated rather quickly. Since most feel that paying for a doctor's consultation entitles them to antibiotics but it's the doctor's job to edify his patients they should not hurry to the doctor if they have a cough for one day or two. Doctors usually say waiting 5 to 7 days is best because then if it is bronchitis, you can tell.  This means if you have a viral infection and severe cough. Once the infection goes away and the cough stays, that's the instance to visit the doctor.  If you give viral infections antibiotics, resistance can build up, leaving you with nothing to use for medicine. Enhancing your vocabulary is our intention with the writing of this article on Bronchitis Respiratory. We have used new and interesting words to achieve this.

  • Studies are undergoing to develop better treatments and antibiotics to combat the tracheal bronchitis.
  • Here is hoping that before the nasty bacteria settles in the tubes that the new medicines are already out on the market.
  • Using our imagination has helped us create a wonderful article on Bronchitis.
  • Being imaginative is indeed very important when writing about Bronchitis!
Quote
Physicians and doctors must have a immense appreciativeness of the organisms so they can know how to manage tracheal bronchitis and many other respiratory illnesses. They must also be acutely aware of all of the therapies effective enough to treat the disease.

Offer Action Against Primary Organisms
Pharmacokinetic   best possible pharmacologic   Experimental response rates are soaring   Penetration of tissue Even the beginner will get to learn more about Pneumonia Bronchitis after reading this article. It is written in easy language so that everyone will be able to understand it.

Coupled with data that is unusable by the time it's ready to be tested, doctors rely on patient's physical examinations to diagnosis the disease. Often they make the diagnosis based on what they see or observe in patients but scientific approaches are still important for the antimicrobial therapy design. Suppressing our knowledge on Bronchitis Condition is not our intention here. In fact, we mean to let everyone know more about Bronchitis Condition after reading this!

Bronchitis is a Condition in Which the Bronchial Tubes are Irritated and Inflamed
There are three specific categories of bronchitis including acute, chronic and bronchiectasis. This is a dependable source of information on Bronchitis Respiratory. All that has to be done to verify its authenticity is to read it!

Antibiotics must meet certain criteria including effectiveness in its treatment, the safety of drugs, cost-effectiveness and convenience. Doctors feel the ideal antibiotic would treat all of the following: We have avoided adding flimsy points on Bronchitis Cough, as we find that the addition of such points have no effect on Bronchitis Cough.

The late 1990's, two medicines called gatifloxacin and moxifloxacin were released which offered better options cough causes symptoms & treatments. When new drugs are introduced, others are often removed because of certain dangerous side effects. We have included some fresh and interesting information on Bronchitis Condition. In this way, you are updated on the developments of Bronchitis Condition.

Drug Interaction Low
Low or no side effects   Bacteria resistance is slow in developing.  Traditional antibiotics include the ever accepted Amoxicillin, macrolides and cephalosporins and greatly used in the antimircobial therapy. Yet, there usefulness fluctuates along with its resistance frequency.

The fluoroquinolones are a relatively new group of antibiotics. Fluoroquinolones were first introduced in 1986, but they are really modified quinolones, a class of antibiotics, whose accidental discovery occurred in the early 1960.

All of the fluoroquinolones are effective in treating urinary tract infections caused by susceptible organisms. They are the first-line treatment of acute uncomplicated cystitis in patients who cannot tolerate sulfonamides or TMP, who live in geographic areas with known resistance > 10% to 20% to TMP-SMX, or who have risk factors for such resistance. It was with great optimism that we started out on writing this composition on Bronchitis. Please don't let us lose this optimism.

Third Generation
The third-generation fluoroquinolones are separated into a third class because of their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens such as Mycoplasma pneumoniae and Chlamydia pneumoniae. Although the third-generation agents retain broad gram-negative coverage, they are less active than ciprofloxacin against Pseudomonas species.

Fluoroquinolones advantages:    Ease of administration Daily or twice daily dosing  Excellent oral absorption Excellent tissue penetration  Prolonged half-lives Significant entry into phagocytic cells Efficacy Overall safety

The fluoroquinolones are a family of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of the group is nalidixic acid, discovered in 1962 by Lescher and colleagues. The first fluoroquinolones were widely used because they were the only orally administered agents available for the treatment of serious infections caused by gram-negative organisms, including Pseudomonas species. Patience was exercised in this article on Bronchitis. Without patience, it would not have been possible to write extensively on Bronchitis.

Because of concern about hepatotoxicity, trovafloxacin therapy should be reserved for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and the drug should be taken for no longer than 14 days.

Classification of Fluoroquinolones
As a group, the fluoroquinolones have excellent in vitro activity against a wide range of both gram-positive and gram-negative bacteria. The newest fluoroquinolones have enhanced activity against gram-positive bacteria with only a minimal decrease in activity against gram-negative bacteria. Their expanded gram-positive activity is especially important because it includes significant activity against Streptococcus pneumoniae.

Conditions Treated With Fluoroquinolones: Indications and Uses
The newer fluoroquinolones have a wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones have an important role in the treatment of community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of the fluoroquinolones range from 3 -20 hours, allowing for once or twice daily dosing.

The newer fluoroquinolones have a wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones have an important role in the treatment of community-acquired pneumonia and intra-abdominal infections. We have actually followed a certain pattern while writing on Chronic Bronchitis. We have used simple words and sentences to facilitate easy understanding for the reader.

Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin is the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are the most widely used second-generation quinolones because of their availability in oral and intravenous formulations and their broad set of FDA-labeled indications. Penetration into the world of Bronchitis proved to be our idea in this article. Read the article and see if we have succeeded in this or not! :)

Gastrointestinal Effects
The most common adverse events experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in 1 to 5% of patients.  CNS effects. Headache, dizziness, and drowsiness have been reported with all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have been reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should be avoided in patients with a history of convulsion, cerebral trauma, or anoxia. No seizures have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. With the older non-fluorinated quinolones neurotoxic symptoms such as dizziness occurred in about 50% of the patients.  Phototoxicity. Exposure to ultraviolet A rays from direct or indirect sunlight should be avoided during treatment and several days (5 days with sparfloxacin) after the use of the drug. The degree of phototoxic potential of fluoroquinolones is as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin. Musculoskeletal effects. Concern about the development of musculoskeletal effects, evident in animal studies, has led to the contraindication of fluoroquinolones for routine use in children and in women who are pregnant or lactating.  Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within one week of discontinuation of therapy, spontaneous ruptures have been reported as long as nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant use of corticosteroids. Hepatoxicity. Trovafloxacin use has been associated with rare liver damage, which prompted the withdrawal of the oral preparations from the U.S. market. However, the IV preparation is still available for treatment of infections so serious that the benefits outweigh the risks. Cardiovascular effects. The newer quinolones have been found to produce additional toxicities to the heart that were not found with the older compounds. Evidence suggests that sparfloxacin and grepafloxacin may have the most cardiotoxic potential. Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects have been mild. Hypersensitivity. Hypersensitivity reactions occur only occasionally during quinolone therapy and are generally mild to moderate in severity, and usually resolve after treatment is stopped. We consider that we have only touched the perimeter of information available on Bronchitis. There is still a lot more to be learnt!

Because of their expanded antimicrobial spectrum, third-generation fluoroquinolones are useful in the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.

Share on Facebook Share on Twitter